Alba A Brandes Selected Research

Lomustine (CCNU)

10/2022	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.
1/2021	Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
1/2020	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling.
11/2019	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.
1/2019	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
11/2017	Lomustine and Bevacizumab in Progressive Glioblastoma.
5/2017	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
1/2016	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
5/2014	Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?
11/2013	New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alba A Brandes Research Topics

Disease

60	Neoplasms (Cancer) 10/2022 - 05/2002
59	Glioblastoma (Glioblastoma Multiforme) 04/2022 - 01/2002
28	Glioma (Gliomas) 01/2021 - 05/2002
17	Disease Progression 01/2020 - 02/2003
13	Brain Neoplasms (Brain Tumor) 10/2022 - 05/2002
9	Oligodendroglioma 01/2019 - 06/2006
8	Breast Neoplasms (Breast Cancer) 11/2020 - 09/2004
8	Medulloblastoma 01/2020 - 10/2003
7	Astrocytoma (Pilocytic Astrocytoma) 01/2022 - 12/2003
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 05/2009
3	Lymphoma (Lymphomas) 01/2020 - 10/2009
3	Cognitive Dysfunction 01/2019 - 05/2004
3	Neoplasm Metastasis (Metastasis) 09/2017 - 10/2004
2	Pituitary Neoplasms (Pituitary Adenoma) 01/2022 - 01/2020
2	Meningioma (Meningiomas) 01/2021 - 01/2020
2	Lymphopenia (Lymphocytopenia) 01/2021 - 09/2014
2	Vomiting 01/2020 - 12/2007
2	Nausea 01/2020 - 12/2007
2	Necrosis 11/2019 - 11/2013
2	Adenocarcinoma of Lung 01/2017 - 01/2017
2	Fatigue 11/2016 - 05/2015
2	Colorectal Neoplasms (Colorectal Cancer) 05/2016 - 05/2014
2	Neutropenia 05/2015 - 09/2014
1	Central Nervous System Neoplasms 01/2022
1	Adenoma (Adenomas) 01/2022
1	Seizures (Absence Seizure) 08/2020
1	Epilepsy (Aura) 08/2020
1	Spinal Cord Neoplasms (Spinal Cord Tumors) 01/2020
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2020
1	Head and Neck Neoplasms (Head and Neck Cancer) 12/2017
1	Primary Ovarian Insufficiency 05/2017
1	Infertility (Sterility) 05/2017
1	Virus Diseases (Viral Diseases) 11/2016
1	HIV Infections (HIV Infection) 11/2016

Drug/Important Bio-Agent (IBA)

48	Temozolomide (Temodar)FDA LinkGeneric 04/2022 - 01/2002
19	Bevacizumab (Avastin)FDA Link 01/2022 - 10/2009
18	Lomustine (CCNU)FDA Link 10/2022 - 02/2003
12	Procarbazine (Matulane)FDA Link 10/2022 - 01/2002
12	Vincristine (Oncovin)FDA LinkGeneric 10/2022 - 01/2002
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2003
9	Biological ProductsIBA 01/2020 - 02/2007
7	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022 - 11/2013
6	Trastuzumab (Herceptin)FDA Link 11/2020 - 08/2007
6	MethyltransferasesIBA 04/2018 - 10/2006
5	ErbB Receptors (EGF Receptor)IBA 01/2017 - 02/2008
5	Pharmaceutical PreparationsIBA 06/2015 - 10/2002
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2014 - 02/2007
4	NivolumabIBA 04/2022 - 12/2017
3	Hormones (Hormone)IBA 11/2020 - 09/2004
3	Monoclonal AntibodiesIBA 09/2017 - 12/2009
3	Angiogenesis InhibitorsIBA 08/2017 - 05/2011
3	DNA (Deoxyribonucleic Acid)IBA 10/2016 - 10/2006
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2014 - 03/2009
2	pembrolizumabIBA 01/2022 - 12/2017
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
2	MicroRNAs (MicroRNA)IBA 11/2021 - 11/2015
2	taxaneIBA 11/2020 - 06/2015
2	PlatinumIBA 12/2017 - 05/2015
2	LY-2157299IBA 05/2017 - 01/2016
2	Phosphotransferases (Kinase)IBA 05/2017 - 01/2016
2	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2017 - 01/2016
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2017 - 02/2007
2	Tyrosine Kinase InhibitorsIBA 01/2017 - 02/2010
2	fotemustine (Muphoran)IBA 01/2016 - 09/2009
2	Lapatinib (GW572016)FDA Link 11/2013 - 02/2010
2	O-(6)-methylguanineIBA 03/2010 - 10/2006
2	Carmustine (FIVB)FDA Link 03/2009 - 12/2004
2	Imatinib Mesylate (Gleevec)FDA Link 10/2008 - 12/2003
2	Cisplatin (Platino)FDA LinkGeneric 07/2005 - 05/2004
2	thiamine triphosphorate (TTP)IBA 02/2003 - 01/2002
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2022
1	Growth Hormone (Somatotropin)IBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2022
1	IpilimumabIBA 01/2022
1	GadoliniumIBA 12/2021
1	Contrast MediaIBA 12/2021
1	regorafenibIBA 01/2021
1	AnthracyclinesIBA 11/2020
1	Biological FactorsIBA 11/2019
1	Indicators and Reagents (Reagents)IBA 01/2019
1	human ERBB2 proteinIBA 12/2018
1	Codon (Codons)IBA 01/2018
1	Genetic Markers (Genetic Marker)IBA 01/2018
1	AntibodiesIBA 12/2017
1	sonidegibIBA 10/2017
1	Glial Fibrillary Acidic ProteinIBA 05/2017
1	Chemokine CCL22IBA 05/2017
1	LigandsIBA 01/2017
1	onartuzumabIBA 01/2017
1	Gefitinib (Iressa)FDA Link 01/2017

Therapy/Procedure

51	Radiotherapy 10/2022 - 01/2002
47	Drug Therapy (Chemotherapy) 10/2022 - 05/2002
31	Therapeutics 11/2020 - 05/2002
5	Chemoradiotherapy 01/2020 - 05/2008
4	Adjuvant Chemotherapy 12/2007 - 02/2003
3	Immunotherapy 12/2017 - 11/2015
3	Salvage Therapy 09/2009 - 07/2005
2	Adjuvant Radiotherapy 01/2021 - 03/2005
2	Aftercare (After-Treatment) 01/2020 - 12/2007